TY - JOUR
T1 - A sequence-based survey of the complex structural organization of tumor genomes
AU - Raphael, Benjamin J.
AU - Volik, Stanislav
AU - Yu, Peng
AU - Wu, Chunxiao
AU - Huang, Guiqing
AU - Linardopoulou, Elena V.
AU - Trask, Barbara J.
AU - Waldman, Frederic
AU - Costello, Joseph
AU - Pienta, Kenneth J.
AU - Mills, Gordon B.
AU - Bajsarowicz, Krystyna
AU - Kobayashi, Yasuko
AU - Sridharan, Shivaranjani
AU - Paris, Pamela L.
AU - Tao, Quanzhou
AU - Aerni, Sarah J.
AU - Brown, Raymond P.
AU - Bashir, Ali
AU - Gray, Joe W.
AU - Cheng, Jan Fang
AU - de Jong, Pieter
AU - Nefedov, Mikhail
AU - Ried, Thomas
AU - Padilla-Nash, Hesed M.
AU - Collins, Colin C.
N1 - Funding Information:
The work in the CC laboratory was supported by the grants from the NIH/ NCI (R33 CA103068), the Breast Cancer Research Program (8WB-0054), the Susan G Komen for the Cure Foundation (BCTR0601011), the Prostate Cancer Foundation, the Bay Area Breast Cancer Spore (CA5807), and a developmental research program award from UCSF brain tumor SPORE. BJR is supported by a Career Award at the Scientific Interface (CASI) from the Burroughs Wellcome Fund, and a fellowship from the Alfred P Sloan Foundation. The work in the BJT laboratory was supported by NIH RO1 GM057070. SJA is supported by a William R Hewlett Stanford Graduate Fellowship and a National Science Foundation Fellowship. RPB is supported by a Ruth L Kirschstein National Research Service Award - NIH Bioinfor-matics Training Grant number GM00806-06. KJP is supported by SPORE P50 CA69568. JWG is supported by the Director, Office of Science, Office of Basic Energy Sciences, of the US Department of Energy under Contract Number DE-AC02-05CH11231, by the USAMRMC BC 061995, and by the National Institutes of Health, National Cancer Institute grants P50 CA 58207, the P50 CA 83639, the P30 CA 82103, the U54 CA 112970, the U24 CA 126477 and the P01 CA 64602, the NHGRI U24 CA 126551, and by the SmithKline Beecham Corporation grant to JWG. The work in the J-FC laboratory was supported by National Heart, Lung, and Blood Institute, Programs for Genomic Applications Grant Number UO1HL66728. The work in the TR laboratory was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
PY - 2008/3/25
Y1 - 2008/3/25
N2 - Background: The genomes of many epithelial tumors exhibit extensive chromosomal rearrangements. All classes of genome rearrangements can be identified using end sequencing profiling, which relies on paired-end sequencing of cloned tumor genomes. Results: In the present study brain, breast, ovary, and prostate tumors, along with three breast cancer cell lines, were surveyed using end sequencing profiling, yielding the largest available collection of sequence-ready tumor genome breakpoints and providing evidence that some rearrangements may be recurrent. Sequencing and fluorescence in situ hybridization confirmed translocations and complex tumor genome structures that include co-amplification and packaging of disparate genomic loci with associated molecular heterogeneity. Comparison of the tumor genomes suggests recurrent rearrangements. Some are likely to be novel structural polymorphisms, whereas others may be bona fide somatic rearrangements. A recurrent fusion transcript in breast tumors and a constitutional fusion transcript resulting from a segmental duplication were identified. Analysis of end sequences for single nucleotide polymorphisms revealed candidate somatic mutations and an elevated rate of novel single nucleotide polymorphisms in an ovarian tumor. Conclusion: These results suggest that the genomes of many epithelial tumors may be far more dynamic and complex than was previously appreciated and that genomic fusions, including fusion transcripts and proteins, may be common, possibly yielding tumor-specific biomarkers and therapeutic targets.
AB - Background: The genomes of many epithelial tumors exhibit extensive chromosomal rearrangements. All classes of genome rearrangements can be identified using end sequencing profiling, which relies on paired-end sequencing of cloned tumor genomes. Results: In the present study brain, breast, ovary, and prostate tumors, along with three breast cancer cell lines, were surveyed using end sequencing profiling, yielding the largest available collection of sequence-ready tumor genome breakpoints and providing evidence that some rearrangements may be recurrent. Sequencing and fluorescence in situ hybridization confirmed translocations and complex tumor genome structures that include co-amplification and packaging of disparate genomic loci with associated molecular heterogeneity. Comparison of the tumor genomes suggests recurrent rearrangements. Some are likely to be novel structural polymorphisms, whereas others may be bona fide somatic rearrangements. A recurrent fusion transcript in breast tumors and a constitutional fusion transcript resulting from a segmental duplication were identified. Analysis of end sequences for single nucleotide polymorphisms revealed candidate somatic mutations and an elevated rate of novel single nucleotide polymorphisms in an ovarian tumor. Conclusion: These results suggest that the genomes of many epithelial tumors may be far more dynamic and complex than was previously appreciated and that genomic fusions, including fusion transcripts and proteins, may be common, possibly yielding tumor-specific biomarkers and therapeutic targets.
UR - http://www.scopus.com/inward/record.url?scp=43249096825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43249096825&partnerID=8YFLogxK
U2 - 10.1186/gb-2008-9-3-r59
DO - 10.1186/gb-2008-9-3-r59
M3 - Article
C2 - 18364049
AN - SCOPUS:43249096825
SN - 1474-7596
VL - 9
JO - Genome biology
JF - Genome biology
IS - 3
M1 - R59
ER -